Patents by Inventor Jean-Maurice Dumont

Jean-Maurice Dumont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Near full-genome assay of HCV drug resistance
    Patent number: 8911934
    Abstract: The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: December 16, 2014
    Assignees: Debiopharm SA, Katholieke Universiteit Leuven
    Inventors: Grégoire Vuagniaux, Jean-Maurice Dumont, Joke Snoeck, Sonia Van Dooren, Anne-Mieke Vandamme
  • Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events
    Patent number: 8889629
    Abstract: The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: November 18, 2014
    Assignee: Debiopharm International SA
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Grégoire Vuagniaux
  • NEAR FULL-GENOME ASSAY OF HCV DRUG RESISTANCE
    Publication number: 20140187765
    Abstract: Assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 3, 2014
    Applicants: Katholieke Universiteit Leuven, Debiopharm SA
    Inventors: Gregoire Vuagniaux, Jean-Maurice Dumont, Joke Snoeck, Sonia Van Dooren, Anne-Mieke Vandamme
  • NEAR FULL-GENOME ASSAY OF HCV DRUG RESISTANCE
    Publication number: 20100311038
    Abstract: The invention relates to assays for characterization of genotypic mutations of Hepatitis C Virus (HCV) showing a resistance to anti-HCV drugs.
    Type: Application
    Filed: October 31, 2008
    Publication date: December 9, 2010
    Applicants: DE-BIOPHARM SA, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Grégoire Vuagniaux, Jean-Maurice Dumont, Joke Snoeck, Sonia Van Dooren, Anne-Mieke Vandamme
  • Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin
    Patent number: 7772184
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Grant
    Filed: August 26, 2008
    Date of Patent: August 10, 2010
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay
  • Use of a cyclosporin for the treatment of hepatitis C infection and pharmaceutical composition comprising said cyclosporin
    Publication number: 20090081164
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Application
    Filed: August 26, 2008
    Publication date: March 26, 2009
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay
  • Use Of A Cyclic Undecapeptide For The Preparation Of A Medicament For Administration During Myocardial Ischaemic Events
    Publication number: 20090023640
    Abstract: The invention relates to the use of a cyclic undecapeptide, with the structure in formula (I), for the preparation of a medicament for administration during a myocardial ischaemic event.
    Type: Application
    Filed: January 10, 2006
    Publication date: January 22, 2009
    Applicant: DEBIOPHARM S.A.
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux
  • Use of selected cyclosporins for the treatment of hepatitis C infection
    Patent number: 7439227
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Grant
    Filed: April 12, 2006
    Date of Patent: October 21, 2008
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay
  • Use Of [D-Meala]3-[Etval]4-Cyclosporin For The Treatment Of Hepatitis C Infection And Pharmaceutical Composition Comprising Said [D-Meala]3-[Etval]4-Cyclosporin
    Publication number: 20080139463
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Application
    Filed: October 3, 2005
    Publication date: June 12, 2008
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay
  • Use of selected cyclosporins for the treatment of hepatitis C infection
    Publication number: 20060252675
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Application
    Filed: April 12, 2006
    Publication date: November 9, 2006
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay
  • Use of selected cyclosporins for the treatment of hepatitis C infection
    Patent number: RE43371
    Abstract: This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 8, 2012
    Inventors: Pietro Scalfaro, Jean-Maurice Dumont, Gregoire Vuagniaux, Rolland-Yves Mauvernay